Vaccines Medical Development and Scientific and Clinical Affairs, Pfizer, Inc., Collegeville, Pennsylvania.
Department of Social and Preventive Medicine, Laval University, Quebec City, Canada.
Clin Infect Dis. 2019 May 30;68(12):2135-2143. doi: 10.1093/cid/ciy920.
The 13-valent pneumococcal conjugate vaccine (PCV13) is the only licensed PCV with serotype 3 polysaccharide in its formulation. Postlicensure PCV13 effectiveness studies against serotype 3 invasive pneumococcal disease (IPD) in children have shown inconsistent results. We performed a systematic review and meta-analysis of observational studies to assess PCV13 vaccine effectiveness (VE) for serotype 3 IPD in children. We systematically searched PubMed, Embase, and the Cochrane library for studies published before 14 August 2017. We identified 4 published studies and 2 conference posters that provided PCV13 VE estimates stratified by serotype. The pooled PCV13 VE against serotype 3 IPD from the random-effects meta-analysis was 63.5% (95% confidence interval [CI], 37.3%-89.7%). A sensitivity analysis including conference posters gave a pooled VE estimate of 72.4% (95% CI, 56.7%-88.0%). The pooled data from case-control studies with similar methodologies and high quality support direct PCV13 protection against serotype 3 IPD in children.
13 价肺炎球菌结合疫苗（PCV13）是唯一一种在其配方中包含 3 型多糖的有许可 PCV。上市后 PCV13 对儿童 3 型侵袭性肺炎球菌病（IPD）的有效性研究结果不一致。我们进行了一项系统评价和荟萃分析，以评估 PCV13 疫苗对儿童 3 型 IPD 的有效性（VE）。我们系统地搜索了 PubMed、Embase 和 Cochrane 图书馆，以查找截至 2017 年 8 月 14 日之前发表的研究。我们确定了 4 项已发表的研究和 2 项会议海报，这些研究和海报提供了按血清型分层的 PCV13 VE 估计值。来自随机效应荟萃分析的针对 3 型 IPD 的 PCV13 总体 VE 为 63.5%（95%置信区间[CI]，37.3%-89.7%）。包括会议海报的敏感性分析得出的总体 VE 估计值为 72.4%（95%CI，56.7%-88.0%）。来自病例对照研究的汇总数据具有相似的方法和高质量，支持 PCV13 对儿童 3 型 IPD 的直接保护作用。
